(Q36753315)

16 August 2017

1 reference

title

Challenges in tuberculosis drug research and development (English)

1 reference

16 August 2017

0 references

Ann M Ginsberg

1

1 reference

16 August 2017

Melvin Spigelman

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

13

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

290-294

1 reference

https://scigraph.springernature.com/pub.10.1038/nm0307-290

16 August 2017

exact match

0 references

cites work

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

Global epidemiology of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Global incidence of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Outpatient gatifloxacin therapy and dysglycemia in older adults

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Chemotherapy of pulmonary tuberculosis in young adults; an analysis of the combined results of three Medical Research Council trials.

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

STREPTOMYCIN treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Clinical development of anti-tuberculosis drugs

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNM0307-290

7 January 2021

Identifiers

DOI

10.1038/NM0307-290

1 reference

Dimensions Publication ID

16 August 2017

1041210294

0 references

1 reference